

## Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1.-18. (Canceled)

19.-26. (Canceled)

27. (Canceled)

28. (Once Amended) The composition of claim [27]30 wherein the antibody fragment binds p185<sup>HER2</sup>.

29. (Once amended) The composition of claim [27]30 wherein the antibody fragment binds CD18.

30. (Once Amended) A composition comprising a physiologically acceptable carrier, and a mixture of incorrectly disulfide linked antibody fragment and correctly disulfide linked antibody fragment, wherein the purity of the correctly disulfide linked antibody fragment in the composition is at least about 95%, and wherein the antibody fragment is selected from the group consisting of a F(ab')<sub>2</sub> fragment, Fab fragment, Fab' fragment and linear F(ab')<sub>2</sub> fragment.

31. (Canceled)

**SUMMARY**

Applicants respectfully submit that the resubmitted "Amendments to the Claims" section complies with the requirements of 37 CFR § 1.121 and cures any deficiencies in the response submitted October 14, 2003.

If in the opinion of the Examiner, a telephone conference would expedite the prosecution of the subject application, the Examiner is strongly encouraged to call the undersigned at the number indicated below.


In the unlikely event that this document is separated from the transmittal letter or if fees are required, applicants petition the Commissioner to authorize charging our Deposit Account 07-0630 for any fees required or credits due and any extensions of time necessary to maintain the pendency of this application.

Applicants respectfully request that a timely Notice of Allowance be issued in this case.

Date: November 17, 2003

Respectfully submitted,  
GENENTECH, INC.

By:

  
Deirdre L. Conley  
Reg. No. 36,487  
Telephone No. (650) 225-2066

Doc # 144735